Mike J. Pishvaian, MD, PhD; Stacey Cohen, MD; and Mark Lewis, MD, FASCO, discuss how recent advancements in circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are revolutionizing colorectal cancer management across the care continuum, from early detection to treatment selection and monitoring, with key insights from major clinical trials like DYNAMIC and GALAXY informing more personalized and effective treatment strategies.
EP. 1: Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
October 16th 2024Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.
EP. 2: ctDNA in CRC Management: Evolving Approaches for Personalized Care
October 16th 2024Panelists discuss how circulating tumor DNA (ctDNA) is revolutionizing colorectal cancer (CRC) management by enabling more personalized and precise approaches to diagnosis, treatment selection, and monitoring of disease progression.
EP. 3: MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring
October 22nd 2024Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.
EP. 4: MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control
October 22nd 2024Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.
EP. 5: DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
October 29th 2024Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.
EP. 6: ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies
October 29th 2024Panelists discuss how insights from the INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY studies are advancing our understanding of circulating tumor DNA’s (ctDNA) utility in colorectal cancer management, from early detection to treatment monitoring.
EP. 7: GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC
November 5th 2024Panelists discuss how the GALAXY study data demonstrate the effectiveness of circulating tumor DNA (ctDNA)–based minimal residual disease (MRD) monitoring in patients with resected colorectal cancer (CRC), potentially improving postsurgical care and outcomes.
EP. 8: GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC
November 5th 2024Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.